NOAC Treatment in Chronic Renal Impairment

On 12 November 2014, Radcliffe Cardiology, in association with Arrhythmia & Electrophysiology Review (AER) journal, held a roundtable discussion in London, UK. The discussion held between an expert group of physicians was moderated by Professor A John Camm, a renowned authority in anticoagulatio...

Full description

Saved in:
Bibliographic Details
Published in:Arrhythmia & electrophysiology review 2015-05, Vol.4 (1S1)
Main Author: Jean-Yves Le Heuzey
Format: Article
Language:English
Subjects:
Anticoagulants
Cardiac arrhythmia
Cardiology
Drug dosages
Heart
Kidney diseases
Laboratories
Patients
Prevention
Stroke
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On 12 November 2014, Radcliffe Cardiology, in association with Arrhythmia & Electrophysiology Review (AER) journal, held a roundtable discussion in London, UK. The discussion held between an expert group of physicians was moderated by Professor A John Camm, a renowned authority in anticoagulation and atrial fibrillation. The meeting comprised a series of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants (NOACs): real-world versus clinical trial data; once or twice daily dosing regimens; spot checks or monitoring for anticoagulation status; antidotes for NOACs; NOACs and dual antiplatelet therapy; NOAC treatment in chronic renal impairment; and choosing between NOACs. This paper summarises the presentations and presents key highlights from the subsequent discussions.
ISSN:2050-3369
2050-3377
DOI:10.15420/aer.2015.4.1.S1